Cellnovo: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company

10/06/17 12:00 PM EDT

Cellnovo: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company

Article L233-8-II of the Commercial code
Article 223-16 of the General Regulations of the Autorité des Marchés Financiers

Regulatory News:

Cellnovo (Paris:CLNV):

Market: Euronext Paris
Compartment: Compartment C
ISIN code: FR0012633360
Website: www.cellnovo.com

Date   Total number of shares(1)   Total number of voting rights
    Total gross
voting rights (2)
  Total net
voting rights (3)
September 30, 2017   16,545,356   16,545,356   16,530,427

(1) Including 450,000 shares since the implementation of the contract of Equity line financing concluded with Kepler Cheuvreux on 17th March 2017 and 4,069,769 shares by means of a capital increase on 7th July 2017.

(2) The number of gross voting rights (or “theoretical” number of voting rights) serves as the basis for calculating the threshold crossings. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares carrying voting rights, including shares without voting rights.

(3) The number of net voting rights (or voting rights “exercisable at the General Assembly") is calculated without taking into account the shares with suspended voting rights. It is disclosed for the proper information of the general public, in accordance with the AMF recommendation dated July 17, 2007.

About Cellnovo

An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.

For further information please visit www.cellnovo.com

Cellnovo is listed on Euronext, Compartment C

ISIN: FR0012633360 – Ticker: CLNV

Cellnovo
Chief Executive Officer
Sophie Baratte
investors@cellnovo.com
or
NewCap
Investor Relations
Tristan Roquet Montégon, + 33 1 44 71 00 16
Media Relations in France
Nicolas Merigeau, + 33 1 44 71 94 98
cellnovo@newcap.eu
or
Consilium Strategic Communications
Media Relations in United Kingdom
Amber Fennell, Chris Welsh, Laura Thornton, +44 20 3709 5700
cellnovo@consilium.com